Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Src, a nonreceptor tyrosine kinase, is a key mediator for multiple signaling pathways that regulate critical cellular functions and is often aberrantly activated in a number of solid tumors, including ovarian carcinoma. The purpose of this study was to determine the role of activated Src inhibition on tumor growth in an orthotopic murine model of ovarian carcinoma. In vitro studies on HeyA8 and SKOV3ip1 cell lines revealed that Src inhibition by the Src-selective inhibitor, AP23846, occurred within 1 hour and responded in a dose-dependent manner. Furthermore, Src inhibition enhanced the cytotoxicity of docetaxel in both chemosensitive and chemoresistant ovarian cancer cell lines, HeyA8 and HeyA8-MDR, respectively. In vivo, Src inhibition by AP23994, an orally bioavailable analogue of AP23846, significantly decreased tumor burden in HeyA8 (P = 0.02), SKOV3ip1 (P = 0.01), as well as HeyA8-MDR (P < 0.03) relative to the untreated controls. However, the greatest effect on tumor reduction was observed in combination therapy with docetaxel (P < 0.001, P = 0.002, and P = 0.01, for the above models, respectively). Proliferating cell nuclear antigen staining showed that Src inhibition alone (P = 0.02) and in combination with docetaxel (P = 0.007) significantly reduced tumor proliferation. In addition, Src inhibition alone and in combination with docetaxel significantly down-regulated tumoral production of vascular endothelial growth factor and interleukin 8, whereas combination therapy decreased the microvessel density (P = 0.02) and significantly affected vascular permeability (P < 0.05). In summary, Src inhibition with AP23994 has potent antiangiogenic effects and significantly reduces tumor burden in preclinical ovarian cancer models. Thus, Src inhibition may be an attractive therapeutic approach for patients with ovarian carcinoma. (Cancer Res 2006; 66(17): 8633-9)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
c-Src and cooperating partners in human cancer
Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617 · cited 2×
“Src, a nonreceptor tyrosine kinase of 60 kDa, is a particularly attractive target because it is activated in a majority of ovarian cancers and regulates a myriad of intracellular signal cascades responsible for critical tumor cell functions through extracellular stimulation by growth factors, growth hormones, and inte…”
BackgroundActivation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., & Gallick, G. E. (2002) · Cancer · doi:10.1002/cncr.10221 · Cited by 251 · cited 1×
“In fact, Src activation has been correlated with tumor prognosis in colorectal and breast carcinomas (28, 29).”
BackgroundSelf-citationDuxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1183-3 · Cited by 192 · cited 1×
“Src is known to promote chemoresistance, and its inhibition restores sensitivity through the activation of caspase-3-mediated apoptosis (14, 17, 21, 42).”
BackgroundPengetnze, Y., Steed, M., Roby, K. F., Terranova, P. F., & Taylor, C. C. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.012 · Cited by 107
Cited by
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462
Self-citationLin, Y. G., Kunnumakkara, A. B., Nair, A., Merritt, W. M., Han, L. Y., Armaiz-Pena, G. N., Kamat, A. A., Spannuth, W. A., Gershenson, D. M., Lutgendorf, S. K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3072 · Cited by 440
Self-citationThe Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346
Merritt, W. M., Lin, Y. G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn024 · Cited by 257
Self-citationEl‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
Metadata
- Authors
- Han, L. Y., Landen, C. N., Trevino, J. G., Halder, J., Lin, Y. G., Kamat, A. A., Kim, T.-J., Merritt, W. M., Coleman, R. L., Gershenson, D. M., Shakespeare, W. C., Wang, Y., Sundaramoorth, R., Metcalf, C. A., Dalgarno, D. C., Sawyer, T. K., Gallick, G. E., & Sood, A. K.
- Venue
- Cancer Research
- Published
- 2006-09-01
- Volume
- 66
- Issue
- 17
- Pages
- 8633-8639
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2170726369
- Cited by
- 94
- References
- 6
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1410
- The paper
- Han, L. Y., Landen, C. N., Trevino, J. G., Halder, J., Lin, Y. G., Kamat, A. A., Kim, T.-J., Merritt, W. M., Coleman, R. L., Gershenson, D. M., Shakespeare, W. C., Wang, Y., Sundaramoorth, R., Metcalf, C. A., Dalgarno, D. C., Sawyer, T. K., Gallick, G. E., & Sood, A. K. (2006). Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.